Vistagen Therapeutics, Inc. Common Stock
VTGNVistagen Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel psychological and neurological treatments. It specializes in innovative medicines for mental health and neurological disorders, leveraging its proprietary research platform to address unmet medical needs.
Company News
A class action lawsuit has been filed against Vistagen Therapeutics, Inc. alleging that the company made materially false and misleading statements regarding its fasedienol drug candidate and the PALISADE-3 clinical trial. Investors who purchased Vistagen securities between April 1, 2024 and December 16, 2025 may be eligible to join the lawsuit, ...
The Rosen Law Firm has announced investigations into potential securities claims against Phoenix Education Partners, Inc. (PXED) following allegations of materially misleading business information. The investigation was triggered by a January 3, 2026 Fox News report of a major data breach affecting 3.5 million people at University of Phoenix, wit...
Rosen Law Firm has filed a class action lawsuit on behalf of Vistagen Therapeutics common stock purchasers between April 1, 2024 and December 16, 2025. The lawsuit alleges that defendants made positive statements about the fasedienol drug trial (PALISADE-3) while simultaneously concealing material negative facts, causing investors to purchase sha...
Rosen Law Firm has filed a securities class action lawsuit on behalf of Vistagen Therapeutics investors who purchased stock between April 1, 2024 and December 16, 2025. The lawsuit alleges that defendants made materially false and misleading statements regarding the fasedienol drug's Phase 3 PALISADE-3 clinical trial, causing investors to purchas...
The Portnoy Law Firm has announced a class action lawsuit against Vistagen Therapeutics on behalf of investors who purchased securities between April 1, 2024 and December 16, 2025. The lawsuit alleges that Vistagen made false and misleading statements about its fasedienol drug candidate, creating a false impression of Phase 3 trial success. On De...
